626 related articles for article (PubMed ID: 30176834)
1. Rationale and design of the Caloric Restriction and Exercise protection from Anthracycline Toxic Effects (CREATE) study: a 3-arm parallel group phase II randomized controlled trial in early breast cancer.
Kirkham AA; Paterson DI; Prado CM; Mackey JR; Courneya KS; Pituskin E; Thompson RB
BMC Cancer; 2018 Sep; 18(1):864. PubMed ID: 30176834
[TBL] [Abstract][Full Text] [Related]
2. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.
Antunes P; Esteves D; Nunes C; Sampaio F; Ascensão A; Vilela E; Teixeira M; Amarelo AL; Joaquim A
Trials; 2019 Jul; 20(1):433. PubMed ID: 31307527
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.
Jacquinot Q; Meneveau N; Chatot M; Bonnetain F; Degano B; Bouhaddi M; Dumoulin G; Vernerey D; Pivot X; Mougin F
BMC Cancer; 2017 Jun; 17(1):425. PubMed ID: 28629338
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of the Diet Restriction and Exercise-induced Adaptations in Metastatic breast cancer (DREAM) study: a 2-arm, parallel-group, phase II, randomized control trial of a short-term, calorie-restricted, and ketogenic diet plus exercise during intravenous chemotherapy versus usual care.
Kirkham AA; King K; Joy AA; Pelletier AB; Mackey JR; Young K; Zhu X; Meza-Junco J; Basi SK; Hiller JP; Brkin T; Michalowski B; Pituskin E; Paterson DI; Courneya KS; Thompson RB; Prado CM
BMC Cancer; 2021 Oct; 21(1):1093. PubMed ID: 34629067
[TBL] [Abstract][Full Text] [Related]
5. Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant Chemotherapy.
Koelwyn GJ; Lewis NC; Ellard SL; Jones LW; Gelinas JC; Rolf JD; Melzer B; Thomas SM; Douglas PS; Khouri MG; Eves ND
Oncologist; 2016 Feb; 21(2):141-9. PubMed ID: 26764251
[TBL] [Abstract][Full Text] [Related]
6. Exercise as a diagnostic and therapeutic tool for preventing cardiovascular morbidity in breast cancer patients- the BReast cancer EXercise InTervention (BREXIT) trial protocol.
Foulkes SJ; Howden EJ; Antill Y; Loi S; Salim A; Haykowsky MJ; Daly RM; Fraser SF; La Gerche A
BMC Cancer; 2020 Jul; 20(1):655. PubMed ID: 32664946
[TBL] [Abstract][Full Text] [Related]
7. Effects of exercise training on cardiac toxicity markers in women with breast cancer undergoing chemotherapy with anthracyclines: a randomized controlled trial.
Antunes P; Joaquim A; Sampaio F; Nunes C; Ascensão A; Vilela E; Teixeira M; Capela A; Amarelo A; Marques C; Viamonte S; Alves A; Esteves D
Eur J Prev Cardiol; 2023 Jul; 30(9):844-855. PubMed ID: 36857149
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol.
Díaz-Balboa E; González-Salvado V; Rodríguez-Romero B; Martínez-Monzonís A; Pedreira-Pérez M; Palacios-Ozores P; López-López R; Peña-Gil C; González-Juanatey JR
BMC Cardiovasc Disord; 2021 Apr; 21(1):165. PubMed ID: 33827450
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH
JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762
[TBL] [Abstract][Full Text] [Related]
10. Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients.
Howden EJ; Bigaran A; Beaudry R; Fraser S; Selig S; Foulkes S; Antill Y; Nightingale S; Loi S; Haykowsky MJ; La Gerche A
Eur J Prev Cardiol; 2019 Feb; 26(3):305-315. PubMed ID: 30376366
[TBL] [Abstract][Full Text] [Related]
11. Cardioprotective effect of Platycodon grandiflorum in patients with early breast cancer receiving anthracycline-based chemotherapy: study protocol for a randomized controlled trial.
Hao W; Liu S; Qin Y; Sun C; Chen L; Wu C; Bao Y
Trials; 2017 Aug; 18(1):386. PubMed ID: 28830541
[TBL] [Abstract][Full Text] [Related]
12. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
Guglin M; Munster P; Fink A; Krischer J
Am Heart J; 2017 Jun; 188():87-92. PubMed ID: 28577685
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.
de Vries Schultink AHM; Boekhout AH; Gietema JA; Burylo AM; Dorlo TPC; van Hasselt JGC; Schellens JHM; Huitema ADR
J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):431-442. PubMed ID: 29429038
[TBL] [Abstract][Full Text] [Related]
14. Effects of physical exercise on outcomes of cardiac (dys)function in women with breast cancer undergoing anthracycline or trastuzumab treatment: study protocol for a systematic review.
Antunes P; Esteves D; Nunes C; Amarelo A; Fonseca-Moutinho J; Afreixo V; Costa H; Alves A; Joaquim A
Syst Rev; 2019 Oct; 8(1):239. PubMed ID: 31651372
[TBL] [Abstract][Full Text] [Related]
15. A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.
Matos E; Jug B; Blagus R; Zakotnik B
Arq Bras Cardiol; 2016 Jul; 107(1):40-7. PubMed ID: 27305108
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.
Schneeweiss A; Chia S; Hickish T; Harvey V; Eniu A; Waldron-Lynch M; Eng-Wong J; Kirk S; Cortés J
Eur J Cancer; 2018 Jan; 89():27-35. PubMed ID: 29223479
[TBL] [Abstract][Full Text] [Related]
17. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
[TBL] [Abstract][Full Text] [Related]
18. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
[TBL] [Abstract][Full Text] [Related]
19. Effects of high-intensity interval training on vascular function in breast cancer survivors undergoing anthracycline chemotherapy: design of a pilot study.
Lee K; Kang I; Mortimer JE; Sattler F; Mack WJ; Fitzsimons LA; Salem G; Dieli-Conwright CM
BMJ Open; 2018 Jun; 8(6):e022622. PubMed ID: 29961039
[TBL] [Abstract][Full Text] [Related]
20. Home-Based Buddhist Walking Meditation Mitigates Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients: A Randomized Controlled Trial.
Siripanya S; Parinyanitikul N; Tanaka H; Suksom D
J Integr Complement Med; 2023 Sep; 29(9):562-573. PubMed ID: 37036793
[No Abstract] [Full Text] [Related]
[Next] [New Search]
